Abstract：
Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [18F]FDG PET/CT is a useful diagnostic modality for this purpose. The clinical indications for, and the principal aspects of its standardization in this context have been detailed in the recently published \"Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0\". These recommendations arose from a fruitful collaboration between international nuclear medicine societies and experts in cancer treatment. In this perspective, the key elements of the initiative are reported, summarizing the core aspects of the guidelines for radiologists and nuclear medicine physicians. Beyond the previous guidelines, this perspective adds further commentary on how this technology can advance development of novel therapeutic approaches and guide management of individual patients.
摘要：
免疫调节治疗背景下的反应评估是医学影像界面临的重大挑战，需要肿瘤学家参与的多学科方法。放射科医生,和核医学专家。不断发展的证据表明，[18F]FDGPET/CT是用于此目的的有用诊断方式。的临床适应症，在最近发表的“关于在免疫调节治疗期间推荐使用[18F]FDGPET/CT成像的联合EANM/SNMMI/ANZSNM实践指南/程序标准”中详细介绍了其标准化的主要方面。实体瘤版本1.0\。这些建议来自国际核医学协会和癌症治疗专家之间的富有成果的合作。从这个角度来看,报告了该倡议的关键要素，总结放射科医师和核医学医师指南的核心方面。除了之前的指导方针，这一观点为这项技术如何促进新治疗方法的开发和指导个体患者的管理提供了进一步的评论.
